# Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

> **NCT07626411** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 15364 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)

## Interventions

- **DRUG:** REGN7508
- **DRUG:** Apixaban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07626411
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2029-09-11
- **Final completion:** 2029-12-10
- **Target enrollment:** 15364 (ESTIMATED)
- **Last updated:** 2026-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07626411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07626411, "Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07626411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*